Michel, Lars
Ferdinandy, Peter
Rassaf, Tienush
Funding for this research was provided by:
Medical Faculty, University Duisburg-Essen, Germany (IFORES Research Grant)
European Co-operation in Science and Technology (COST action CA16225, EU- Cardioprotection)
Hungarian National Research, Development, and Innovation Office (OTKA K 109737, OTKA KH_17 125570, NVKP 16-1-2016-0017, and VEKOP-2.3.2-16-2016- 00002)
Ministry of Human Capacities in Hungary (Higher Education Institutional Excellence Programme)
Deutsche Forschungsgesellschaft (RA 969/12-1)
Universitätsklinikum Essen
Article History
Accepted: 26 February 2024
First Online: 2 March 2024
Declarations
:
: The authors declare no competing interests.
: L.M. reports personal fees from Bayer, Alnylam, AstraZeneca, IFFM e. V. and from Bund der Niedergelassenen Kardiologen (BNK). P.F. is the founder and CEO of Pharmahungary Group, a group of R&D companies. T.R. report personal fees and others from Edwards, Novartis, Bristol Myers Squibb, Bayer, Daiichi Sankyo und AstraZeneca and Pfizer. T.R. is a co-founder of Bimyo, a company focusing on the development of cardioprotective peptides.
: This article does not contain any studies with human or animal subjects performed by any of the authors.